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Abstract 
 
Objective: Cognitive Behaviour Therapy (CBT) has been shown to be effective in the management of Chronic 
Widespread Pain (CWP); we now test whether it can prevent onset among adults at high risk. 
Methods: A population-based randomised controlled prevention trial, with recruitment through UK general practices. 
A mailed screening questionnaire identified adults at high risk of CWP.  Participants received either usual care (UC) or 
a short course of telephone CBT.  The primary outcome was CWP onset at 12 months assessed by mailed 
questionnaire. There were seven secondary outcomes including quality of life (EQ-5D-5L) used as part of a health 
economic assessment.  
Results: 996 participants were randomised and included in the intention-to-treat analysis of which 825 provided 
primary outcome data. The median age of participants was 59 years; 59% were female. At 12 months there was no 
difference in the onset of CWP (tCBT: 18.0% v. UC: 17.5%; OR 1.05; 95% CI 0.75-1.48). Participants who received tCBT 
were more likely to report better quality of life (EQ-5D-5L utility score mean difference 0.024 (95% CI 0.009-0.040)); 
and had  0.023 (95% CI 0.007-0.039) more QALYs at an additional cost of £42.30 (95% CI −451.19-597.90), yielding an 
incremental cost effectiveness ratio of £1,828. Most secondary outcomes showed significant benefit for the 
intervention. 
Conclusions: A short course of tCBT does not prevent onset of CWP in adults at high risk, but did improve quality of 
life and was cost-effective.  A low-cost, short duration, intervention benefits persons at risk of CWP.  
 
Key Messages: 
What is already known about this subject?  
• Cognitive Behaviour Therapy (CBT) has demonstrated long-term effectiveness in managing chronic 
widespread pain, the characteristic symptom of fibromyalgia 
• It improves patient global assessment of change  and quality of life 
What does this study add?  
• A short course of telephone CBT in persons evaluated at high risk of developing CWP does not change onset 
of CWP but does result in a wide range of health benefits including improved quality of life.  
How might this impact on clinical practice or future developments? 
• CBT derives benefit for a wider group of people with pain than previously established and in relation to this 
wider group is highly cost-effective 
Introduction  
 
Chronic widespread pain (CWP) is common, with an estimated population prevalence of 10.6% (95% confidence 
interval (CI) 8.6-12.9) (1) and is the key feature of fibromyalgia which is the second most common reason (after 
osteoarthritis) for referral to a rheumatologist (2). Chronic widespread pain and fibromyalgia result in a substantial 
impact on health-related quality of life (3) even in comparison to other musculoskeletal disorders (4).   
 
The road to diagnosis is often tortuous and can take many years. Using general practitioner records in the United 
Kingdom, Hughes et al (5) noted that people diagnosed with fibromyalgia had higher rates of primary care visits 
(average 25 visits/year), prescriptions (11/year), and testing from at least 10 years prior to diagnosis, in comparison to 
matched persons without such a diagnosis (12 visits/year and 4.5 prescriptions/year). Current European guidelines 
emphasise the primary role of non-pharmacological therapies for fibromyalgia (6). Evidence in relation to 
musculoskeletal pain generally, is that the longer the duration of symptoms, the less likely they are to improve 
including with specific interventions (7).  
 
A Versus Arthritis “Research roadmap for pain” produced by scientists, clinicians and patients identified preventing 
future musculoskeletal pain as one of four main priorities (8). Further recognising its importance, the International 
Association for the Study of Pain nominated 2020 as “The Global Year for the Prevention of Pain”. Despite this, we are 
not aware of any large-scale trials which have tested approaches to the future prevention of pain.  
 
We have previously shown, in a randomised controlled trial, short and long-term effectiveness of a course of Cognitive 
Behaviour Therapy delivered by telephone (tCBT) for CWP, compared to usual care (9.10). These results are consistent 
with a meta-analysis of 29 trials involving 2509 participants and comparing CBT (across all modes of delivery) with 
control interventions for the management of fibromyalgia, which found high quality evidence  for improving pain, 
reducing disability, negative mood and fatigue (11).  
 
We have developed, validated and refined a statistical model which identifies people at high risk for the future 
development of CWP (12,13). On the basis of reporting somatic symptoms, sleep problems and aspects of illness 
behaviour, those classified as “high risk” have around 1 in 4 chance of reporting CWP one year later.  Therefore, 
building upon the evidence for the use of tCBT in the management of CWP and the ability to identify those with risk 
factors for its development, we undertook a trial to test whether tCBT can reduce CWP onset amongst those at high 
risk. 
 
Methods 
 
Study Design  
We conducted a  randomised controlled parallel prevention trial, recruiting through a population-based sampling 
frame,  in three health boards within the United Kingdom (NHS Grampian, NHS Greater Glasgow and Clyde, NHS 
Highland), the protocol for which has been previously published (14). Recruitment was through sixteen general 
practices. Ethical approval was obtained from Cornwall and Plymouth Research Ethics Committee Reference 
16/SW/0019.  
 
Participants 
A short screening questionnaire, to determine eligibility for the trial, was mailed to persons aged 25 years and over 
registered at participating general practices in the study area.  Respondents eligible for the trial were those assessed 
as at high risk of developing CWP, namely that they reported pain which did not satisfy the definition of CWP  used in 
the 1990 American College of Rheumatology criteria for fibromyalgia (namely axial and contra-lateral body pain 
present for at least 3 months), and hereafter referred to as “ACR criteria” (15), and satisfied at least two of the 
following a) a score >4 on the Illness Behaviour Subscale of the Illness Attitudes Scale (16) b) a score >2 on the Somatic 
Symptom Scale (SSS) score (but excluding items on pain) (17) c) a score >= 4 on the Sleep Problem Scale (18). In order 
to ensure that in the event of the trial showing benefit there was a relevant clinical population to which the 
intervention could be applied, we added to the risk models we had developed the requirement that persons had 
consulted to primary care within the previous six months or reported consulting  a doctor frequently. Respondents 
were not eligible to take part if they had a medical condition which would make the proposed intervention unsuitable 
(e.g. lacked cognitive ability).  
 
Randomisation 
Potentially eligible participants were contacted by post with information about the study, and subsequently by a study 
researcher by telephone to confirm their willingness to take part and provide informed consent. Participants were 
allocated into groups using a computer randomisation program (1:1 allocation ratio) , stratified in blocks by two factors 
a) the number of non-pain “high-risk” factors they reported (2 or 3) since this is related to the risk of CWP onset, and 
b) the general practice at which they were registered.  
 
Procedures 
The tCBT intervention consisted of an initial assessment (45–60 min), 6 weekly sessions (each 30–45 min) over six 
weeks, and then booster sessions at 3 and 6 months. The intervention was delivered by therapists trained for the study 
and accredited by the British Association for Behaviour and Cognitive Psychotherapies. Participants were supported 
by a self-management manual. The therapist conducted an assessment for problem identification, and they developed 
with each participant a shared formulation of the current health problem. The sessions involved education about 
musculoskeletal pain, somatic symptoms and specific techniques such as pacing of activity, behavioural activation, 
diary keeping, identifying and challenging negative and unhelpful thinking patterns and the development of a longer-
term management plan. Participants would record in the manuals agreed goals for the therapist and patient to work 
towards, and some activities to complete between sessions. Therapists delivering the intervention received a 2-day 
training programme conducted by the investigators. Therapists were supervised every two weeks (by investigators KL 
and PK) throughout the delivery of the intervention. The number of telephone consultations conducted was recorded, 
although the therapist and participant could jointly agree that no further sessions were required before all planned 
sessions had been completed. 
 
The group allocated to usual care received no additional intervention, reflecting the fact there is no specific 
intervention provided to patients currently for the prevention of CWP. There was no restriction on what this care could 
involve.  
 
Follow-up questionnaires were mailed to participants at 3, 12 and 24 months after the treatment start date (for 
participants in the active treatment group) or dummy treatment start date (for those in usual care). The dummy 
treatment start date for a participant randomised to UC was determined by the treatment start date of the last 
participant to be randomised to receive active treatment. At 3 and 12 months, participants who did not return their 
questionnaire were telephoned to ask them to complete and return it, while at 24 months the follow-up call also 
offered the option of completing a shortened version by telephone.  
 
Outcomes 
The principal outcome time was at 12 months follow-up and the primary outcome was ACR criteria for CWP. Secondary 
outcomes were: Global Impression of Change, Illness Behaviour Subscale of the Illness Attitudes Scale (16), the SSS 
(excluding items on pain) (17), the Sleep Problem Scale (18), the presence of pain over the past month, Widespread 
Pain Index (WPI) and Symptoms Severity Scale (SSS) of the 2010 (revised) criteria for fibromyalgia (19), psychological 
distress measured using by the General Health Questionnaire (GHQ) (20), Chalder Fatigue Scale (21), quality of life 
(EQ-5D-5L) (22) and capability (ICECAP-A)(23). Further details of secondary outcome (including coding) are given in the 
Supplementary Text file.  
 
Statistical Analysis 
All analyses were undertaken using STATA version 15. The a priori target sample size was 946 participants, which would 
provide 90% power to detect a group difference of 9% (21% vs 12%) in the percentage of participants with chronic 
widespread pain (CWP) at 12 months follow-up, assuming a 5% significance level and an 80% response rate. 
 
Where there was missing data within a scale score, we followed standard procedures (where available) as to if and 
how the missing values could be imputed. The analysis of the primary outcome used a binary logistic regression model 
with results expressed as an odds ratio (OR) with 95% CI. Secondary outcomes were analysed using linear, binary 
logistic, ordinal logistic, or Poisson regression models for continuous, binary, ordinal, and count variables respectively.  
Model results were reported using mean differences, odds ratios or incident rate ratios (IRRs) as appropriate. Except 
for EQ-5D-5L, mean differences less than zero and ORs/IRRs less than one favour the treatment group. All models were 
adjusted (adj) for the number of non-pain risk factors on screening (two or three), age (years), gender, general practice 
(random effect) and baseline score of the outcome measure (where applicable). The primary analysis was by intention 
to treat – i.e. participants were analysed according to randomised group regardless of the number of sessions received. 
Separate analyses were performed for each time point (3, 12 and 24 months). For the primary outcome a p-value less 
than 0.05 was regarded as statistically significant; for secondary outcomes p<0.01 was used. Additional sensitivity 
analyses were conducted for the primary outcome only and are detailed in the supplementary text file.  
 
Health Economic Analysis 
Health service resource use over 24 months was assessed using responses from  self-reported questionnaires. 
Participants were asked to recall their usage for the previous 4 week period at each follow-up. Resource use was then 
valued using published UK sources - NHS Reference Cost and the Personal and Social Service Research Unit (PSSRU) 
for NHS primary and secondary care and published literature for care obtained from private providers (24). The unit 
costs used for the valuation of health service resource use are reported in Supplementary Material Table S1. The 
intervention cost was based on the actual number and duration of telephone calls per participant (“direct time”), plus 
time spent on training and supervision. An allowance for indirect time spent was also included and this was based on 
an assumed ratio of 1:1 between time spent on participant contact and other activities conducted by therapist. 
Training costs were estimated using the time spent in training by trainers and trainees (tCBT therapists). A fortnightly 
supervision cost was estimated by assuming 30 sessions per therapist (30 minutes per session) were provided. Costs 
were expressed in 2017/18 prices. Health utility scores were assigned based on responses to the EQ-5D-5L at each 
follow-up, and these were converted using the ‘crosswalk’ procedure to EQ-5D-3L (25). There is currently no consensus 
on the preferred EQ-5D-5L tariff for use in economic evaluation, althoughthe National Institute for Health and Care 
Excellence (NICE) recommend the use of the ‘crosswalk’ procedure (a validated mapping function) to derive health 
utility scores for the EQ-5D-5L from the EQ-5D-3L tariff [https://www.nice.org.uk/about/what-we-do/our-
programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l accessed 20 November 2020]. These utility 
scores were used to estimate quality-adjusted life years (QALYs) over the 24-month using the Area Under the Curve 
(AUC) method (26). Costs and QALYs incurred beyond 12 months were discounted at the rate of 3.5% per annum. 
 
The within-trial economic analysis was conducted over 24 months from a UK National Health Service (NHS) cost 
perspective. To estimate the differences in mean costs and QALYs between groups, generalised linear models with 
adjustment for minimisation factors, baseline cost and baseline utility score were performed. A γ family with log link 
function and a Poisson family with power 0.5 link function were specified for the cost and QALY data, respectively. 
Missing data were addressed using multiple imputation by chained equations (MICE). Variance surrounding the 
incremental costs and QALYs was characterised using non-bootstrapping (500 iterations), with MICE (m=5) nested 
within the bootstrap loops (27). Cost-effectiveness acceptability curves (CEACs) were constructed, using 500 
replications of each incremental cost-effectiveness ratio (ICER) and the net monetary benefit framework, to determine 
the probability of the alternative interventions being considered cost-effective at different willingness to pay (WTP) 
per QALY (£20,000-£30,000 per QALY was used are commonly applied ceiling ratios in the UK). Several sensitivity 
analyses were performed to explore the impact on the results of uncertainty in estimates made – (i) using complete 
cases of costs and QALYS, (ii) including private care costs, (iii) using alternative tCBT costing methodology (actual trial 
expenses incurred by therapists and the cost of a complete tCBT course) and (iv) using ICECAP tariff as the measure of 
effectiveness.  
 
The trial was registered with clinicaltrials.gov (NCT02668003); and was evaluated by the Trial Steering Committee as 
not requiring a Data Monitoring Committee.  
 
Results  
 
Of 61257 screening questionnaires sent, between Apr 4, 2016 and Nov 4, 2016 to patients registered at 16 general 
practices, 18035 completed questionnaires were returned. From those returning a completed questionnaire, 2406 
were identified as potentially eligible and sent invitations to take part in the trial. 1002 participants were recruited to 
the trial and randomised, 501 to tCBT and 501 to UC, between May 2016 - March 2017. Six participants were 
subsequently determined to be ineligible for the trial and were excluded from analyses (see Trial Profile: Figure 1) 
leaving a final study size of 500 and 496 in the tCBT and UC arms respectively.  At the 3, 12- and 24-month follow-up 
there were 823, 825 and 853 respondents who provided primary outcome data, respectively. Most participants (51%) 
came from the lowest two quintiles of deprivation, while 18% came from the two most deprived quintiles. 
 
Participants at the time of recruitment had a median age of 59 years (inter-quartile range (IQR) 48-69), 59% were 
female, and 52% were working full-time or part-time (Table 1).  The median EQ-5D utility score was 0.74 IQR (0.65–
0.80). The vast majority satisfied only two of the non-pain criteria for eligibility, nearly always on the basis of a high 
score on the illness behaviour subscale of the Illness attitudes scale and having sleep problems. Only 6% of the study 
sample satisfied the somatic symptoms criterion. The tCBT and UC groups were well matched in terms of the measured 
health-related factors.  
 
Results for all outcome measures at the primary time point (12 months) are shown in Table 2. The corresponding 
results at 3 and 24 months are shown in Supplementary Material (Tables S2-S3). Table 3 provides a summary of all 
primary and secondary outcomes at all time points and shows adjusted and unadjusted effect sizes. 
 
Primary outcome 
At the 12 month time point similar percentages in the tCBT and UC groups reported having CWP (tCBT: 69/384 (18.0%), 
UC: 77/441 (17.5%); adj OR 1.05; 95% CI: 0.75-1.48; difference in percentages: adj 0.73, 95% CI: -4.15-5.61) (Tables 2-
3). Very similar results were obtained at 3 months (17.9% v. 16.9%; adj OR: 1.08; 95% CI: 0.74-1.58) and 24 months 
(19.6% v. 22.3%; adj OR: 0.85; 95% CI: 0.68-1.07) (Table S2-S3, Table 3). There was no difference in the interpretation 
when examining unadjusted results, per protocol results or the analyses using multiple imputation (Table 3). The GEE 
model, incorporating data from all three time points, also showed no evidence of a difference (adj OR: 1.00; 95% CI: 
0.96 -1.04; p=0.91). 
 
Secondary outcomes 
At 12 months, those randomised to tCBT were more likely to perceive their health to be improved (adj OR (OLR): 0.51, 
95% CI: 0.39-0.67) and to report better quality of life (EQ-5D-5L utility scores) (adj mean diff: 0.024, 95% CI: 0.009-
0.040) (Tables 2-3). While those who received tCBT had lower illness behaviour (adj mean difference (diff): -0.81; 95% 
CI: -1.54--0.09) and sleep problem scores (adj mean diff: -0.95; 95% CI: -1.48--0.42), but there was no significant 
difference in relation to somatic symptoms (adj OR): 0.86; 95% CI: 0.71-1.04).  Participants randomised to tCBT had 
improved distress (GHQ scores) (adj OR: 0.65, 95% CI: 0.50-0.86) and lower levels of fatigue (Chalder scale scores) (adj 
mean diff: -1.02, 95% CI: -1.63--0.42). There was no evidence of a difference for ICECAP-A tariffs (adj OR (OLR): 1.39, 
95% CI: 0.94-2.04; p=0.10). In relation to the components of criteria for fibromyalgia, they had lower scores on the 
WPI (adj IRR: 0.88; 95% CI: 0.80-0.98) and SSS (adj mean diff: -0.52, 95% CI: -0.75--0.28). Of these receiving tCBT, 3.8% 
met fibromyalgia research criteria at follow-up (in comparison to 6.0% amongst those receiving UC). 
   
Outcomes across timepoints 
Sensitivity analyses, unadjusted results and findings at 3- and 24-month time points generally yielded similar 
observations as those for 12 months (Tables 3, S1-S2).  There was consistently no effect on the primary outcome. The 
strongest and most consistent effects were on patient global assessment of change – which showed large and 
consistent effects across all time points. There were also clear effects of the intervention (in comparison to UC) across 
all time points with respect to improvement in levels of fatigue and psychological distress. Quality of life was better in 
the intervention group from twelve months onwards.  There was only one serious adverse event reported, it was in 
the intervention group but unrelated to the intervention.  
 
Health economic analysis 
The unadjusted health service resource use and costs per participant are summarised in Table S4. Participants 
randomised to tCBT group had an average time of 139 minutes of direct contact with therapists over the 6-month t-
CBT course, and the average tCBT cost was £270.19 per participant. Compared to the usual care group, NHS primary 
and secondary care costs were lower amongst tCBT group, and private care costs higher. All cost-effectiveness analyses 
showed that tCBT was associated with an increase in health service costs and an increase in QALYs (Table 4). The 
primary analysis generated a mean of 0.023 (95% CI 0.007-0.039) more QALYs per participant at an additional cost of 
£42.30 (95%CI −£451.19-£597.90), yielding an incremental cost effectiveness ratio (ICER) of £1,828. Based on the 
results of the non-parametric bootstrap, tCBT was found to have a 91.6% chance of being the preferred strategy at a 
ceiling ratio of £20,000 per QALY gained (Figure 2). Sensitivity analyses showed that this finding was robust to changes 
in study perspective, inclusion of complete cases only and different assumptions relating to delivery of the intervention 
in terms of tCBT staff time (Figure S1 a-d).  
 
Discussion 
A short course of tCBT amongst persons at high risk did not change the proportion of people developing CWP 
(compared to UC). Those receiving the active intervention were more likely to perceive their health as having improved 
and report better quality of life as well as lower levels of fatigue and psychological distress. The intervention was highly 
cost effective in terms of incremental cost per QALY gained.  
 
Undertaking a primary prevention study presents different challenges to undertaking a treatment study. Most people 
eligible for the trial probably would not have known what CWP is, nor that they were at high risk of its development. 
Thus, the intervention was described as “maintaining musculoskeletal health” and introduced in the context of 
participants having reported pain and other symptoms. Although a set number of sessions for the intervention was 
planned, it was agreed that at any point the intervention could be stopped with mutual agreement between therapist 
and participant; with the intervention considered completed. Amongst participants, 329 (66%) were considered to be 
completers i.e. had the assessment session and either had at least two completed treatment sessions (n= 297) or had 
the assessment session and up to one treatment session with mutual agreement that the intervention was complete 
(n=32).  Of those classed as “non-completers”, 97 had no assessment while 75 had an assessment and up to one 
treatment session.  
 
Why did the trial clearly not change the likelihood of CWP onset while showing positive effects for a range of secondary 
outcomes (including quality of life)? Firstly, it may be that CBT is not effective in relation to preventing CWP onset. We 
know that there is a large body of evidence that CBT (including tCBT) is effective in relation to managing CWP, and also 
for managing some of the symptoms which characterised people at high risk, but it may not be effective at improving 
the pain in CWP. Our previous trial using CBT in the management of CWP while showing large improvement in patient 
perception of their condition and in quality of life, did not demonstrate any benefit in terms of the Chronic Pain Grade 
(10). Secondly our risk model may not be the causal model. A change in hypothesised risk factors would only effect a 
change in outcome if the relationship was causal. This suggests that it would be beneficial to explore, amongst those 
at risk, what is the underlying causal mechanism. Altered hypothalamic-pituitary-adrenal (HPA) axis function is one 
possible underlying causal mechanism which has been investigated (28).  Thirdly, it is understood that there are life-
course influences, specifically early life factors, on the development of CWP (29), so it could be that intervening across 
the adult age range is too late to be effecting a change by means of a short-term intervention. Fourthly it may be that 
CWP was a poor choice as the primary outcome. There is evidence that people with CWP can move in and out of 
meeting criteria (30) and indeed it may be that we have identified people who commonly experience CWP but 
recruited them at a time when they did not meet criteria - and the interpretation would be that the intervention did 
not move participants off that trajectory. Recent data from a longitudinal study in Norway has shown that the 
transition, amongst people with pain, to CWP did not represent a clinically significant change in state (31).   
 
It is already known that CBT is effective in the management of fibromyalgia (11) and this study provides evidence that 
a wider range of patients may benefit in terms of quality of life. In total 54.5% of the intervention group considered 
their health had improved (between a little and very much) compared to 36.9% of the usual care group, as well as 
improvements in fatigue, distress and changes in response to symptoms. The incremental cost per QALY gained of 
£1828 (which was robust to different assumptions modelled in various sensitivity analyses) means that this 
intervention is highly likely to be cost effective at the limit which the National Institute of Health and Clinical Excellence 
(NICE) in the UK, is willing to pay. In terms of delivering behavioural therapies, it has long been recognised that there 
is a shortage of clinical psychologists in the United Kingdom. It is not necessary to have such persons delivering 
behavioural therapy to all such patients even where cognitive behavioural therapy is identified as appropriate. In this 
study, the intervention was delivered by therapists accredited by the British Association for Behaviour and Cognitive 
Psychotherapies (BABCP). At a minimum this requires a Bachelor of Science degree and a two-year course leading to 
a postgraduate diploma in cognitive behaviour psychotherapies (CBP). Further there has been a considerable amount 
of research in terms of internet-based therapies. The potential advantage of such a self-directed approach is that it 
requires less input by the therapist (usually somewhere between 1-15 mins/week). Further, a meta-analysis of 20 
studies involving 1460 participants showed that internet delivered CBT was effective in the treatment of insomnia (32) 
while a meta-analysis of 20 studies involving 1418 participants comparing face-to-face and internet delivered CBT for 
psychiatric and somatic symptoms found that “there was no evidence to conclude that they were not equivalent” (33). 
Studies have also examined training members of the care team (usually nurses) to deliver behavioural therapy in terms 
of making any service for chronic pain sustainable, and these have been shown to be effective (34). Thus we need to  
consider different professionals and ways of delivering CBT, particularly if we widen the group eligible to receive it, 
and there is no doubt that the large changes to how health services are delivered, caused by COVID-19, will only 
accelerate moves to the greater use of remote delivery of care 
In summary, this trial has shown that a short course of tCBT does not prevent the onset of CWP in adults assessed as 
being at high risk. It did however positively change most other health indicators measured, including quality of life, 
and was highly cost effective. It demonstrates that a low-cost short duration intervention benefits a wider range of 
people with musculoskeletal symptoms than previously considered. 
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Figure Legends 
Figure 1: Trial profile 
 
Figure 2: Cost-effectiveness plane and cost-effectiveness acceptability curve between groups (primary analysis using 
imputed dataset, NHS perspective). Cost-effectiveness planes were based on 500 bootstrap cost-effect pairs 
(adjusted for age, gender, number of risk factors present, employment status, centre, baseline EQ-5D health utility 
score and baseline cost). QALY, quality adjusted life year; tCBT, telephone-delivered cognitive behavioural therapy. 
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Table 1: Baseline characteristics by treatment arm in the ITT population 
 
Characteristic Randomised groups  
 tCBT (n=500) Usual care (n=496) 
 Median (IQR) Median (IQR) 
Age (years) 58.8 (47.7 – 68.7) 59.5 (47.9 – 68.9) 
 N (%) N (%) 
Gender   
Male 
Female 
209 (41.8) 
291 (58.2) 
204 (41.0) 
292 (58.9) 
Employment status   
Working (full or part-time) 
Unable to work because of health 
Retired 
Other  
277 (55.4) 
18 (3.6) 
168 (33.6) 
37 (7.4) 
244 (49.2) 
30 (6.0) 
177 (35.7) 
45 (9.1) 
CWP risk profile:   
Illness behaviour score > 4 
No 
Yes 
Not known* 
Somatic Symptoms Scale score > 2 
No 
Yes 
Sleep problems score > 4 
No 
Yes 
Not known* 
 
1 (0.2) 
498 (99.6) 
1 (0.2) 
 
472 (94.4) 
28 (5.6) 
 
1 (0.2) 
499 (99.8) 
0 (0.0) 
 
2 (0.5) 
494 (99.5) 
0 (0.0) 
 
462 (93.1) 
34 (6.9) 
 
2 (0.4) 
493 (99.4) 
1 (0.2) 
CWP risk profile factors present (N)   
2 
3 
474 (94.8) 
26 (5.2) 
466 (94.0) 
30 (6.0) 
 Median (IQR) [n**] Median (IQR) [n] 
Psychological distress (GHQ) 1 (0 – 4) [499] 1 (0 – 4) [494] 
Quality of Life (EQ-5D-5L utility score) 0.74 (0.65 – 0.80) [499] 0.74 (0.64 – 0.80) [496] 
ICECAP-A 0.91 (0.81 – 0.95) [495] 0.90 (0.79 – 0.95) [491] 
Fibromyalgia Research Criteria   
WPI 
SSS 
3 (1 - 4) [499] 
4 (3 – 6) [497] 
2 (1 – 4) [492] 
4 (3 – 5) [494] 
EQ-5D-5L: Euroqol questionnaire – five dimensions – five levels; FRC: fibromyalgia research criteria; GHQ: 
general health questionnaire; ICECAP-A: ICEpop CAPability measure for Adults; IQR: interquartile range; SD: 
standard deviation; SSS: symptom severity scale; tCBT: telephone cognitive behavioural therapy; WPI: 
widespread pain index.  
 
* Where individuals completed half or fewer items, the score was classified as not known, but individuals could 
still be eligible for recruitment based on their responses to other items answered.  
** The number of persons for whom a scale score could be calculated  
   
Table 2: Outcomes by treatment arm at 12 months (Intention to treat analysis) 
Characteristic Randomised groups 
 tCBT (n=500) Usual care (n=496) 
   
Primary Outcome N (%) N (%) 
Chronic widespread pain   
No 
Yes 
315 (82.0) 
69 (18.0) 
364 (82.5) 
77 (17.5) 
Secondary Outcome   
Global impression of change   
Very much better 
Much better 
A little better 
No change 
A little worse 
Much worse 
Very much worse 
24 (6.5) 
88 (23.7) 
90 (24.3) 
83 (22.4) 
65 (17.5) 
18 (4.9) 
3 (0.8) 
15 (3.5) 
59 (13.8) 
84 (19.6) 
126 (29.4) 
119 (27.7) 
23 (5.4) 
3 (0.7) 
Pain Reported   
No 
Yes 
79 (20.6) 
305 (79.4) 
68 (15.4) 
373 (84.6) 
CWP risk profile   
Somatic symptoms score 
0 
1 
2-5 
Illness behaviour score        Mean (SD)[n*]  
Sleep problems score           Mean (SD)[n] 
 
210 (56.5) 
103 (27.7) 
59 (15.9) 
8.21 (4.04) [371] 
8.20 (4.89) [373] 
 
228 (52.8) 
123 (28.5) 
81 (18.8) 
8.96 (4.19) [431] 
9.20 (5.16) [432] 
Psychological Distress (GHQ score)   
0 
1 
2-5 
6-12 
201 (54.5) 
59 (16.0) 
68 (18.4) 
41 (11.1) 
202 (46.8) 
54 (12.5) 
113 (26.2) 
63 (14.6) 
 Mean (SD) [n] Mean (SD) [n] 
Chalder Fatigue Score 12.6 (4.5) [370] 13.6 (4.4) [433] 
 Median (IQR) [n] Median (IQR) [n] 
Quality of Life (EQ-5D utility score) 0.74 (0.66 – 0.84) [371] 0.74 (0.65 – 0.82) [435] 
ICECAP-A 0.91 (0.82 – 0.97) [368] 0.89 (0.78 – 0.95) [429] 
Fibromyalgia Research Criteria   
WPI 
SSS 
2 (1 - 4) [366] 
3 (2 – 5) [369] 
2 (1 – 4) [427] 
4 (2 – 5) [431] 
EQ-5D-5L: Euroqol questionnaire – five dimensions – five levels; FRC: fibromyalgia research criteria; GHQ: 
general health questionnaire; ICECAP-A: ICEpop CAPability measure for Adults; IQR: interquartile range; SD: 
standard deviation; SSS: symptom severity scale; tCBT: telephone cognitive behavioural therapy; WPI: 
widespread pain index. * The number of persons for whom a scale score could be calculated  
 
Table 3: Summary of the primary and secondary outcomes across follow-up points1 
 
Outcome Time point 
(months) 
Analysis 
method 
(effect size) 
Adjusted* 
effect size 
(95% CI) 
p-
value 
Unadjusted 
effect size 
(95% CI) 
p-value 
Primary Outcome       
CWP 
CWP (per protocol) 
CWP (with multiple 
imputation) 
3 Logistic 
regression 
(OR) 
1.08 (0.74, 
1.58) 
0.691 1.07 (0.75, 
1.53) 
0.716 
1.15 (0.75, 
1.75) 
0.519 1.18 (0.77, 
1.66) 
0.522 
1.06 (0.74, 
1.54) 
0.749 1.05 (0.72, 
1.53) 
0.816 
CWP** 
CWP (per protocol) 
CWP (with multiple 
imputation) 
12 1.05 (0.75, 
1.48) 
0.771 1.04 (0.72, 
1.48) 
0.849 
1.11 (0.81, 
1.50) 
0.519 1.09 (0.74, 
1.60) 
0.673 
1.04 (0.75, 
1.45) 
0.982 1.03 (0.74, 
1.42) 
0.964 
CWP 
CWP (per protocol) 
CWP (with multiple 
imputation) 
24 
  
0.85 (0.68, 
1.07) 
0.163 0.84 (0.61, 
1.18) 
0.317 
0.85 (0.64, 
1.12) 
0.241 0.84 (0.58, 
1.20) 
0.330 
0.85 (0.66, 
1.09) 
0.220 0.84 (0.65, 
1.09) 
0.196 
CWP 3,12,24  GEE (OR) 1.00 (0.96, 
1.04) 
0.923 1.00 (0.96, 
1.04) 
0.835 
Secondary Outcomes 
Global impression of 
change2 
3 Ordinal 
Logistic 
Regression 
(OR) 
0.42 (0.32, 
0.55) 
<0.001 0.43 (0.34, 
0.56) 
<0.001 
12 0.51 (0.39, 
0.67) 
<0.001 0.53 (0.41, 
0.68) 
<0.001 
24 0.55 (0.43, 
0.70) 
<0.001 0.58 (0.45, 
0.73) 
<0.001 
CW
P 
ris
k 
pr
of
ile
 
Somatic symptom 
score 
3 Ordinal 
logistic 
regression 
(OR) 
0.79 (0.60, 
1.03) 
0.084 0.83 (0.64, 
1.08) 
0.173 
12 0.86 (0.71, 
1.04) 
0.112 0.85 (0.65, 
1.11) 
0.237 
24 0.81 (0.59, 
1.12) 
0.206 0.90 (0.67, 
1.21) 
0.498 
Illness behaviour score 3 Linear 
regression 
(Mean 
difference) 
-0.17 (-0.58, 
0.24) 
0.385 -0.25 (-0.79, 
0.29) 
0.360 
12 -0.81 (-1.54, -
0.09) 
0.030 -0.74 (-1.32, -
0.17) 
0.011 
24 -1.25 (-2.15, -
0.35) 
0.010 -1.20 (-1.83, -
0.58) 
<0.001 
Sleep problems score 3 Linear 
regression 
(Mean 
difference) 
-0.62 (-1.26, 
0.02) 
0.057 -0.62 (-1.31, 
0.08) 
0.081 
12 -0.95 (-1.48, -
0.42) 
0.002 -1.00 (-1.70, -
0.30) 
0.005 
24 -0.51 (-1.25, 
0.23) 
0.161 -0.52 (-1.39, 
0.16) 
0.117 
 
1 Analyses shaded in grey favour tCBT over usual care at pre-specified significance level for secondary outcomes (p<0.01).  
Except for EQ-5D-5L, mean differences less than zero and odds ratios less than one favour the treatment group.  
2 OR of one point increase in global impression of change score (worsening of health) 
Psychological distress (GHQ) 3 Ordinal 
logistic 
regression 
(OR) 
0.55 (0.43, 
0.69) 
<0.001 0.58 (0.45, 
0.76) 
<0.001 
12 0.65 (0.50, 
0.86) 
0.002 0.70 (0.54, 
0.90) 
0.007 
24 0.76 (0.60, 
0.96) 
0.024 0.74 (0.56, 
0.98) 
0.037 
Chalder fatigue score 3 Linear 
Regression 
(Mean 
difference) 
-1.36 (-2.10, -
0.64) 
0.001 -1.40 (-1.97, -
0.82) 
<0.001 
12 -1.02 (-1.63, -
0.42) 
0.003 -1.03 (-1.64, -
0.42) 
0.001 
24 -0.93 (-1.62, -
0.23) 
0.012 -0.93 (-1.58, -
0.27) 
0.006 
Quality of Life (EQ-5D-5L 
utility score) 
3 Linear 
Regression 
(Mean 
difference) 
0.009 (-0.009, 
0.028) 
0.304 0.021 (-0.004, 
0.046) 
0.101 
12 0.024 (0.009, 
0.040) 
0.004 0.037 (0.010, 
0.064) 
0.007 
24 0.030 (0.009, 
0.050) 
0.008 0.040 (0.011, 
0.069) 
0.007 
ICECAP-A tariff 3 Ordinal 
logistic 
regression 
(OR) 
1.14 (0.89, 
1.48) 
0.304 1.17 (0.86, 
1.59) 
0.323 
12 1.39 (0.94, 
2.04) 
0.096 1.39 (1.01, 
1.91) 
0.042 
24 0.88 (0.67, 
1.15) 
0.338 0.99 (0.70, 
1.41) 
0.966 
Fi
br
om
ya
lg
ia
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rit
er
ia
 
Widespread Pain 
Index 
3 Poisson 
Regression 
(IRR) 
0.98 (0.90, 
1.07) 
0.698 1.01 (0.93, 
1.10) 
0.771 
12 0.88 (0.80, 
0.98) 
0.018 0.92 (0.84, 
0.99) 
0.036 
24 0.88 (0.78, 
0.98) 
0.022 0.92 (0.84, 
1.00) 
0.058 
Symptom Severity 
Scale 
3 Linear 
Regression 
(Mean 
difference) 
-0.28 (-0.52, -
0.04) 
0.026 -0.25 (-0.57, 
0.65) 
0.118 
12 -0.52 (-0.75, -
0.28) 
<0.001 -0.59 (-0.91, -
0.27) 
<0.001 
24 -0.29 (-0.55, -
0.02) 
0.040 -0.28 (-0.61, 
0.05) 
0.100 
CI: confidence interval; CWP: chronic widespread pain; EQ5D-5D-5L: Euroqol questionnaire – five dimensions – five levels; GEE: 
generalised estimating equations with unstructured correlation structure; GHQ: general health questionnaire; ICECAP-A: ICEpop 
CAPability measure for Adults; IRR: incident rate ratio; OR: odds ratio; 
*Adjusted analyses control for the number of risk factors (two or three), age, gender, baseline score (if applicable) and centre 
(random effect).  Analyses are intention-to-treat unless otherwise stated. ** Primary outcome.  
Table 4: Adjusted3 mean incremental costs, incremental QALYs, and incremental cost-effectiveness ratio over 24 months between tCBT vs usual care  
Analysis Mean costs, (95% CI) Mean QALYs, (95% CI) Incremental mean 
costs,  
£ (95% CI)4  
Incremental 
mean QALYs 
(95% CI)  
ICER 
(£/QALY) 
 
 
tCBT Usual care tCBT Usual care 
Imputed dataset/ITT analysis (NHS 
perspective)5 
3094.68 
(1775.65- 
9074.15) 
3052.38 
(1735.77- 
8567.24) 
1.254 (1.238-
1.270) 
1.231 (1.215- 
1.245) 
42.30 (-451.19-
597.90) 
0.023 (0.007-
0.039) 
1,828 
SA: Complete cases (NHS perspective)6 2684.53 
(1817.69- 
5221.86) 
2454.67 
(1645.66- 
4769.87) 
1.444 (1.415-
1.471) 
1.420 (1.392- 
1.447) 
229.86 (-228.74-
734.09) 
0.024 (-0.005-
0.053) 
9,608 
SA: Imputed dataset (NHS + private care 
perspective) 
4239.22 
(2135.82- 
15332.80) 
4149.10 
(2110.98- 
14039.06) 
1.253 (1.238-
1.270) 
1.231 (1.215- 
1.247)  
90.12 (-475.79-
772.98) 
0.022 (0.007-
0.039) 
4,022 
SA: Imputed dataset using actual trial 
expenses (NHS perspective)7 
3128.61 
(1809.54- 
9164.04) 
3027.54 
(1734.31- 
8587.83) 
1.254 (1.238-
1.270) 
1.231 (1.215- 
1.245) 
101.07 (-373.14-
641.98) 
0.023 (0.007-
0.039) 
4,367 
SA: Imputed dataset using the cost of a 
complete tCBT course (NHS perspective)8 
3314.57 
(1966.93- 
9059.99) 
2960.98 
(1729.67- 
7781.19) 
1.254 (1.238-
1.270) 
1.231 (1.215- 
1.245) 
353.59 (-80.46-
1,238.07) 
0.023 (0.007-
0.039) 
15,280 
SA: Imputed dataset using ICECAP (NHS 
perspective)9 
4659.66 
(1764.56- 
10400.07) 
4787.56 
(1815.05- 
10632.20) 
1.288 (1.278-
1.297) 
1.275 (1.266- 
1.284) 
-127.90 (-603.19-
545.33) 
0.013 (0.003-
0.023)10 
 
NA 
 
3 Adjusted for baseline differences (age, gender, number of risk factors present, employment status, centre, baseline EQ-5D health utility score and baseline cost). 
4 Bootstrapped non-parametric 95% confidence interval (2.5th/97.5th centile). Generalised linear model with γ distribution and log-link function to estimate incremental costs and generalised linear model with Poisson distribution and 
power 0.5 link function to estimate incremental QALYs/years of full capacity. Discounted at 3.5% per year  
 
5 Imputed dataset is the ITT analysis. Missing values were imputed to account for all participants included in the ITT analysis.  
6 593 complete cases were included (tCBT, n=297 and usual care, n=326). Complete cases are those with no missing data on cost and health utility at each time point.  
7 Included the actual trial expenses per tCBT participant, £301. This was estimated using the lump-sum trial expenses incurred by therapists, including therapists’ training and tCBT delivery. 
8 Included the cost of a complete tCBT course per participant, £443. Time spent by therapist, training and supervision were included. The total time spent by the therapist was estimated by assuming that all tCBT participants attended a 
complete tCBT course consisting of 9 sessions.  
9 Adjusted for baseline differences (age, gender, number of risk factors present, employment status, centre, baseline ICECAP value and baseline cost). 
10 Incremental years of full capability. 
 
 
QALYs, quality-adjusted life-years; ICER, incremental cost-effectiveness ratio; NA, not applicable; SA, sensitivity analysis. 
 
 
 Supplementary Text 
 
Methods 
 
The Scottish Index of multiple deprivation was used to determine the quintile of deprivation of participants based on 
their area of residence, assessed by their postcode (SIMD, 2016).  
 
Details of Secondary Outcomes 
Secondary outcomes collected in the study were as follows: 
 
- Global Impression of Change (of health since entering the trial), a single-item measure of seven six categories 
(very much better, much better, a little better, no change, a little worse, much worse and very much worse), 
although the latter two categories were combined for analysis due to low numbers; 
- the presence of pain over the last month and number of pain sites (measured by the Widespread Pain Index 
(score 0-19) of the “research” (or 2010 revised) criteria for fibromyalgia (20). In addition, we measured the 
Symptom Severity Scale (SSS: score 0-12) which are also part of the fibromyalgia criteria set. Participants with 
WPI ≥7 & SSS ≥ 5, or WPI 3-6 & SSS ≥9, and who reported having such symptoms for at least 3 months, meet 
criteria for fibromyalgia. 
- the “risk profile” for CWP as assessed by the Illness Behaviour Subscale of the Illness Attitudes Scale (16), the 
Somatic Symptom Scale score (but excluding items on pain) (17), and the Sleep Problem Scale (18). The Illness 
Attitudes Scale measures attitudes and concerns about illness and health. A study using principal component 
analysis (Speckens et al, 1996) showed that the IAS consisted of two subscales, one of which related to illness 
behaviour (6 items), scoring from 0-24, with higher scores associated with undertaking specific behaviours. 
The Somatic Symptom Scale was originally devised as a screening tool for somatisation and consists of 5 non-
pain items (0-5, with higher scores indicating more somatic symptoms). The Sleep Problem Scale consists of 
four items measuring sleep problems over the past four weeks with score range 0-20, higher scores indicating 
greater frequency of sleep problems; 
- psychological distress measured using  the 12-item General Health Questionnaire (GHQ)(20) and analysed 
using an ordinal model with the categories 0 (least distress), 1, 2-5 and 6-12 (most distress); 
- fatigue measured using the Chalder Fatigue Scale (11 items with scores 0-33, higher scores representing more 
disabling and severe  fatigue) (21);  
- quality of life measured using the five-item, five level EQ-5D-5L (-0.59 representing the worst possible quality 
of life and 1 the best possible) (22);  
- capability using the 5-item ICECAP-A (ICEpop CAPability measure for Adults) which focusses on wellbeing, and 
analysed using an ordinal model with categories 0-0.49 (worst quality of life), 0.5-0.79 and 0.8-1.0 (best quality 
of life) (23); 
 
Sensitivity analyses 
 
Sensitivity analyses were conducted for the primary outcome only. These included an analysis excluding participants 
who did not complete the active intervention (per protocol analysis) and an analysis using multiple imputation (see 
Royston, 2004). For the per protocol analysis, participants in the intervention group were included if they had the 
initial assessment with the therapist and it was mutually agreed to stop the treatment, or if they had the initial 
assessment plus at least 2 more sessions with the therapist. Missing values for CWP at each time point were imputed 
using the mi package in STATA using the following variables: age, gender, number of risk factors and GP practice. 
Twenty imputed datasets were created, using an adjusted logistic regression model. An additional analysis for CWP 
incorporating all three follow-up time points in one model was also conducted using generalised estimating equations 
using an unstructured correlation structure (see Zeger et al, 1988). The model was adjusted for covariates and results 
expressed as an OR with 95% CI. 
 
Additional requirements in CONSORT reporting of trials  
 
Randomisation: The randomisation was undertaken by a member of the study team contacting, using internet or 
telephone, the trial randomisation centre at the Centre for Healthcare Randomised Trials at the University of 
Aberdeen. The participants were informed of the allocated group during the consent/randomisation phone call. The 
study statistician was blinded to which group received the “active” treatment until the statistical analysis had been 
completed. 
 
Generalisability: The trial recruited from very different areas of Scotland. It included urban areas in Glasgow and 
Aberdeen with very different levels of deprivation, rural areas in Aberdeenshire and remote areas across the 
Highlands. Recruitment through a population-sampling frame maximises generalisability. Our previous (qualitative) 
work in terms of telephone delivery of CBT has shown that this can improve access both in remote and rural areas 
(because care can be obtained without long distance travel) and in urban areas (since it overcomes, for example, 
difficulties in getting time off work or in arranging suitable care for dependents) (Bee et al, 2010; Bee et al, 2016).   
Harms: It was not envisaged that the intervention would lead to harms, but procedures were designed to support any 
participants who became distressed during the sessions.   
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18035 questionnaires 
assessed for eligibility 
2450 eligible 
15585 ineligible 
1002 randomised 
501 assigned  
tCBT 
501 assigned 
Usual care 
496 included in 
intention-to-treat 
analysis 
0 discontinued treatment 
501 treatment 
completed 
329 treatment 
completed 
500 included in 
intention-to-treat 
analysis 
172 discontinued treatment 
59 no response to letters 
113 participant withdrew 
( 38 no reason given; 28 did 
not have time; 20 perceived 
study as not relevant; 13 felt 
they were managing; 6 
disliked some aspect of study; 
8 other reason)  
61257 questionnaires 
posted out to patients 
5 post-
randomisation 
exclusions 
1 post-
randomisation 
exclusion 
2406 invited 
 
 
